医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®

2021年04月28日 PM07:33
このエントリーをはてなブックマークに追加


 

LOS ANGELES

ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a strategic supply agreement with Health & Happiness (H&H) Group, a global leader in premium health, human and pet nutrition and personal care brands. The agreement provides H&H Group with rights to ChromaDex’s patented nicotinamide riboside ingredient Niagen®, the sole active ingredient in Tru Niagen®, for exclusively formulated Swisse® products. Tru Niagen® is an industry-leading, award-winning dietary supplement that helps users Age Better® by safely and effectively increasing NAD+ (nicotinamide adenine dinucleotide) levels which are critical to healthy cellular function and vitality. Levels of NAD+ decline with age as well as metabolic stressors including stress on the immune system, sleep disruption, sun exposure, and alcohol consumption.

“This arrangement with H&H Group advances the ChromaDex objectives of building a global consumer brand while working with exceptional strategic partners,” says company CEO Rob Fried. “The Swisse® and Tru Niagen® brands share a common mission to improve human health around the world.”

Niagen® will be offered to H&H Group consumers under the company’s Swisse® product family, a global nutrition brand with a presence in four continents and Australia’s No. 1 wellness brand. The Swisse range includes multivitamins, dietary supplements, sports nutrition, skincare and functional foods. The new products will be the first NAD+ boosters in the Swisse® portfolio and will expand its healthy aging category.

H&H Group Executive Director and CEO Laetitia Garnier said the company was excited to be making this announcement alongside ChromaDex and expressed the opportunity for the companies and consumers alike.

“At H&H Group, we are committed to seeking out the best ingredients so that our formulations can be of the highest quality and deliver innovative and efficacious solutions to consumers. When we have the opportunity to combine that with ground-breaking innovation such as Niagen® it is a really exciting proposition for us and our customers.

“We are impressed by the clinical evidence and the team that sits behind Niagen®. We look forward to working together to explore product development and provide our health-conscious consumers with many health benefits that will come from the leading NAD+ boosting nutrient.”

Niagen® increases NAD+ levels safely and effectively, as demonstrated in nine published human trials. Niagen® has achieved regulatory acceptance by the world’s four leading regulatory bodies: the U.S. FDA, Health Canada, the European Commission, and the Therapeutic Goods Administration (TGA) of Australia.

For additional information about ChromaDex, please visit www.chromadex.com.

For additional information on H&H Group, please visit www.hh.global.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.truniagen.com and through partnerships with global retailers and distributors. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

About H&H Group:

H&H Group is a global health and nutrition company, dynamic, courageous and ambitious to inspire wellness, while contributing positively to the needs of society and the planet. The Group has three business segments – Baby, Adult and Pet Nutrition and Care – supporting whole-family health and happiness, with premium brands providing nutrition and wellness solutions backed by science. Consumer brands include Swisse, Biostime, Solid Gold Pet, Dodie, Good Goût, Aurelia Probiotic Skincare and CBII.

The Group runs the Biostime Institute for Nutrition and Care, and has research and development centres in Europe, China and Australia. Its NewH2 corporate innovation arm invests in the world’s emerging technologies in health, nutrition and wellness.

H&H Group is globally headquartered in Hong Kong SAR and listed on the Hong Kong Stock Exchange (“H&H INTL HLDG” stock code 1112), with more than 3,000 team operating across 14 countries – Australia, New Zealand, Greater China, India, Singapore, Malaysia, Thailand, France, Italy, Switzerland, the Netherlands, Ireland, England and the United States.

The Group is part of the world’s largest corporate social responsibility initiative, the UN Global Compact and is committed to becoming a B Corporation by 2025.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended including statements related to whether the arrangement with H&H Group will advance the company’s objectives of building a global consumer brand. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could” or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005124/en/

CONTACT

ChromaDex Media Contact:

Alex Worsham, Vice President of Global Marketing & Communications

310-388-6706 ext. 689

alexw@chromadex.com

ChromaDex Investor Relations Contact:

Brianna Gerber, Vice President of Finance and Investor Relations

949-419-0288 ext. 127

briannag@chromadex.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 亚马逊与美国国家安全委员会携手开展业界首创合作项目,以解决美国常见的工伤问题
  • Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline
  • 片肺換気中の高酸素血症介在疾患の罹患率にORiを指針とする酸素需要評価が及ぼす影響についての新研究
  • セルトリオン、抗COVID-19モノクローナル抗体治療剤「Regdanvimab(CT-P59)」の グローバル第3相臨床試験結果を発表
  • 沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台,树立高分辨质谱性能新标杆